In a ground-breaking revelation, pharmaceutical behemoth Novo Nordisk has disclosed that its well-known obesity medicine, Wegovy, considerably lowers the risk of cardiovascular events, such as heart attacks and strokes, in addition to being successful in reducing weight. The news, which was announced on Tuesday, represents a key turning point in the field of obesity therapy and shows that this weight-loss medication has additional medical uses in addition to its intended one.
Novo Nordisk Reveals Medical Benefits of Wegovy Extend to Cardiovascular Health
Even though Novo Nordisk hasn't yet made the whole study data public, the preliminary findings may have wide-ranging effects.
Dr. Shauna Levy, the medical director of the Tulane Bariatric Center in New Orleans and an expert in obesity medicine, said that the study's possible effects would cause insurance companies to rethink covering Wegovy despite its relatively expensive cost. Because the medication is seen as optional, many people have had trouble getting insurance coverage for it, according to NBC News.
The study examined the impact of Wegovy on people with pre-existing cardiovascular disease and a history of overweight or obesity. It featured a late-stage clinical trial with more than 17,000 persons aged 45 and over. Along with usual treatment, participants either got a 2.4-milligram dosage of Wegovy or a placebo. Notably, the findings showed an astounding 20% decrease in the risk of cardiovascular events for individuals using Wegovy, pointing to a possible development in the fight against heart disease, the main cause of mortality in the US.
Dr. Holly Lofton, director of the weight management program at NYU Langone Health and an investigator in the Novo Nordisk trial, emphasized that these findings could help dispel the perception of Wegovy as a purely cosmetic drug, combating the stigma associated with weight-related medications. The study's outcomes could contribute to changing the narrative around obesity treatments and highlighting the critical health benefits they offer.
While the precise mechanisms leading to these cardiovascular benefits remain under investigation, Novo Nordisk has assured that Wegovy appears to be safe and well-tolerated, consistent with previous clinical trials. The company's eagerness to share additional details about the trial during its upcoming earnings call further underscores the significance of these findings.
Notably, Wegovy shares an active ingredient, semaglutide, with another Novo Nordisk medication, Ozempic, initially developed for Type 2 diabetes but also prescribed off-label for weight loss. The widespread demand for both Wegovy and Ozempic reflects the growing recognition of the potential benefits of these medications beyond their established uses.
GLP-1 Agonists Offer Cardiovascular Health Boosts with Cautionary Notes
As approximately half of U.S. adults struggle with obesity, according to the Centers for Disease Control and Prevention, the potential impact of Wegovy's cardiovascular benefits cannot be understated. Dr. Levy anticipates that these findings merely scratch the surface of the potential health advantages offered by medications like Wegovy and Ozempic.
Nevertheless, the insurance industry's response to these developments remains uncertain. AHIP, an insurance industry trade group, refrained from making definitive statements about potential coverage changes, emphasizing the need for comprehensive evaluations of prescription drugs beyond manufacturer press releases.
Despite the promising results, it is important to recognize that Wegovy, along with similar GLP-1 agonist drugs like Ozempic, may not be suitable for all individuals. These medications can entail serious side effects such as abdominal discomfort, nausea, vomiting, and pancreatitis.
Nonetheless, Novo Nordisk intends to petition the Food and Drug Administration to include cardiovascular benefits on Wegovy's prescription label later this year, opening the door to a new era in obesity treatment and prevention.
Related Article: Rise in Child and Teen Weight-loss Surgeries, Study Reveals
